

# TABLE OF CONTENTS

January 18, 2010

No. 2172

## BUSINESS

- 1 Common Approval System Needed in Asia: Mr Shoda
- 2 Top Management Stresses Need to Develop New Products in New Year's Speeches
- 3 Reform of Distribution Practices and Drug Pricing System Are Two Sides of the Same Coin: Mr Bessho
- 3 Responses to New Pricing System Most Important Challenge for Wholesalers: Mr Kohno
  - Makers Must Explain Meaning of New Pricing System to Buyers: Mr Matsutani
- 4 Eisai Completes Acquisition of AkaRx
- 4 Kyowa Kirin Licenses Bardoxolone from Reata
- 5 Meiji Seika Aims at Becoming "Specialty & Generic" Pharma
- 5 Mochida, MTPC to Comarket Escitalopram
- 6 **BUSINESS NEWS IN BRIEF**
  - Daiichi Sankyo Acquires PharmaForce through Luitpold
  - Novartis Obtains Diovan's Successor by Acquiring Corthera
  - AnGes Terminates Cross Licensing Agreement for NF-kB
  - 1st Product Using Elan's DDS Technology Approved in Japan

## REGULATORY

- 8 Hatoyama Administration's 1st Budget Proposal for FY2010 Approved by Cabinet
  - *Koroshō*'s Budget Up 9.5% to ¥27,556.1 Bil.
  - PFSB's Budget Down 32.6% to ¥10,281 Mil.
  - HPB's Budget Down 8.9% to ¥194.3 Bil.
  - HSB's Budget Up 33.3% for Anticancer Measures
- 9 New Growth Strategy to Focus on Health, Environment, Tourism
- 10 DSP Applies for Lurasidone in the US
- 10 Teijin Pharma Applies for TMX-67 in Japan
- 10 **REGULATORY NEWS IN BRIEF**
  - Herceptin Receives Positive Opinion for Advanced Stomach Cancer from CHMP
- 11 **Commentary**
  - Industry Must Make Further Investment in R&D to Introduce Better Pricing System

## GENERICS

- 12 Reorganization of Generics Industry to Progress: Mr Sawai
- 12 NJIHK to Start *Hansha*'s MS Certification System

## R&D

- 13 Japan, China, South Korea to Start Joint Studies on Ethnic Differences
- 13 **R&D NEWS IN BRIEF**
  - BI Conducts PIII Trials for 2 Anticancer Agents
  - Avastin + Chemotherapy Improves PFS in Advanced Breast Cancer Patients
  - Tykerb + Herceptin Prolongs OS in Advanced Breast Cancer Patients
  - Rivaroxaban Reduces Recurrence of Symptomatic VTE: Bayer
  - Kitasato Ins., Keio Univ. Chosen as Global Clinical Research Centers

## MEDICAL FACILITIES & NURSING CARE

- 15 Improvement of Infrastructures Essential to Promote Development of Biomarkers
- 15 KRAS Gene Test Conducted in Only 12% of Patients
- 16 Proposed GL for Oral Hypoglycemic Agents Requires Long-Term Studies on All Two-Drug Combinations
  - Use of Surrogate Markers Recommended to Assess CV Risk
- 17 Prof. Yamanaka Shows Great Hope for CP-690550 as 4th-Generation Immunosuppressant
- 17 **Survey**
  - Fall in the Number of OB/GYN Doctors Halted: *Koroshō*
- 18 Transplacental Administration of Antiarrhythmic Agents Given Conditional Approval
- 19 JMA Opposed to Any Decrease in Repeat Consultation Fee Clinics
- 19 **TOPICS**
  - 3 Novartis A (H1N1) 2009 Flu Vaccines Prequalified by WHO
- 18 **ON THE MOVE**
  - Ichiro Umeda Appointed Chairman of PhRMA JBEC
  - Hiroshi Sawai Appointed Director of Sales Division at GSK